Ribometrix is a platform therapeutics company discovering small molecule drugs that target functional 3D RNA structures to treat human diseases.
Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.
Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston.
Location: United States, North Carolina, Durham
Employees: 11-50
Total raised: $45.3M
Investors 4
| Date | Name | Website |
| 08.11.2022 | M Ventures | m-ventures... |
| - | Illumina V... | illuminaVe... |
| - | SV Health ... | svhealthin... |
| - | MP Healthc... | mp-healthc... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 27.09.2019 | - | $7.8M | - |
| 15.11.2018 | Series A | $30M | - |
| 31.10.2017 | Seed | $7.5M | - |
Mentions in press and media 23
| Date | Title | Description |
| 07.04.2024 | Ribometrix Presents First c-MYC Data Validating RNA-Targeting Platform and Demonstrates Synergistic Potential of eIF4E Program at AACR 2024 | -- First data disclosure from Ribometrix’s RNA-targeting drug discovery platform identifies small molecules targeting c-MYC, a validated but historically undruggable cancer driver -- Data shows direct binding of small molecules to c-MYC RNA... |
| 11.03.2024 | Ribometrix to Present New Preclinical Data From RNA-Modulating Small Molecule Programs Targeting eIF4E and c-MYC at the 2024 AACR Annual Meeting | — Data demonstrate in vivo tumor regression via RNA-binding protein inhibitor targeting eIF4E in multiple tumor types with significant unmet need — — First data disclosure from the Company’s RNA-targeting small molecule platform and its pro... |
| 29.12.2019 | Wrapping Up CLT’s 2019: Q4 Deals in the Queen City | An exciting Q4 in the Carolinas has left many startups looking forward to a successful 2020. We thought the best way to ring in the new year would be to look back at the most noteworthy fundings, deals, exits, mergers, and acquisitions duri... |
| 27.09.2019 | DDF notes Ribometrix raises $7.8 Million in New Funding to Advance RNA-Targeting Drug Discovery Platform with Investment from DDF | The Dementia Discovery Fund notes that Ribometrix, a biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases, has announced $7.8 million in additional funding from existing investors, th... |
| 27.09.2019 | Ribometrix Raises $7.8M in Funding | Ribometrix, a Durham, N.C.-based biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases, raised $7.8m in funding. Backers included existing investors the Dementia Discovery Fund and Ill... |
| 27.09.2019 | Ribometrix Announces $7.8 Million in New Funding to Advance RNA-Targeting Drug Discovery Platform | - |
| 27.09.2019 | Ribometrix Announces $7.8M Financing | DURHAM, N.C.--(BUSINESS WIRE)--Ribometrix, a biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases, today announced $7.8 million in additional funding from existing investors, the Deme... |
| 27.09.2019 | Biotech startup Ribometrix raises $7.8M funding to develop small molecule drugs that directly target RNA to treat human diseases | Ribometrix, an early stage biotechnology startup that is discovering and developing small molecule drugs to treat human diseases, has rasied $7.8 million in additional funding to advance its RNA-targeting drug discovery platform. The new ca... |
| 27.09.2019 | Ribometrix Announces $7.8M in New Funding | DURHAM, NC, Ribometrix announced $7.8 million in additional funding. >> Click here for more funding data on Ribometrix >> To export Ribometrix funding data to PDF and Excel, click here Ribometrix, a biotechnology company ... |
| 15.11.2018 | DDF notes Ribometrix $30 Million Series A Financing | The Dementia Discovery Fund notes that Ribometrix, a biotechnology company developing small molecule therapeutics that directly target RNA to treat human diseases, has announced the closing of a $30 million Series A financing. |
Show more